Up a level |
Digklia, A; Kollár, A; Dietrich, D; Kronig, M N; Britschgi, C; Rordorf, T; Joerger, M; Krasniqi, F; Metaxas, Y; Colombo, I; Ribi, K; Rothermundt, C (2024). SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. European journal of cancer, 197(113470), p. 113470. Elsevier 10.1016/j.ejca.2023.113470
de With, M; Sadlon, A; Cecchin, E; Haufroid, V; Thomas, F; Joerger, M; van Schaik, R H N; Mathijssen, R H J; Largiadèr, C R (2023). Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO open, 8(2), p. 101197. BMJ 10.1016/j.esmoop.2023.101197
Schmid, S; Jochum, W; Padberg, B; Demmer, I; Mertz, K D; Joerger, M; Britschgi, C; Matter, M S; Rothschild, S I; Omlin, A (2022). How to read a next-generation sequencing report-what oncologists need to know. ESMO open, 7(5), p. 100570. BMJ 10.1016/j.esmoop.2022.100570
Hamzic, Seid; Wenger, N; Fröhlich, Tanja; Joerger, M; Aebi, Stefan; Largiadèr, Carlo Rodolfo; Amstutz, Ursula (2017). The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics journal, 17(4), pp. 319-324. Nature Publishing Group 10.1038/tpj.2016.23
Hamzic, Seid; Kummer, Dominic; Milesi, S; Mueller, D; Joerger, M; Aebi, S; Amstutz, Ursula; Largiadèr, Carlo Rodolfo (2017). Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clinical pharmacology & therapeutics, 102(5), pp. 796-804. Wiley 10.1002/cpt.641
Mueller, F; Büchel, B; Köberle, D; Schürch, Stefan; Pfister, B; Krähenbühl, St; Fröhlich, Tanja; Largiader, C R; Joerger, M (2013). Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology, 71(2), pp. 361-70. Berlin: Springer 10.1007/s00280-012-2018-4
von Rohr, L; Klaeser, B; Joerger, M; Kluckert, T; Cerny, T; Gillessen, S (2007). Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie, 30(6), pp. 320-3. Basel: Karger 10.1159/000101517
Joerger, M; Metaxas, Y; Schmitt, AM; Koeberle, D; Zaman, K; Betticher, D; Mach, N; Renner, C; Mark, M; Petrausch, U; Caspar, C; Britschgi, C; Taverna, C; Zenger, F; Mingrone, W; Schulz, J; Kopp, C; Hayoz, S; Stathis, A and von Moos, R (2020). Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) (Unpublished). In: Virtual ESMO 2020.